research use only

Pimicotinib CSF-1R inhibitor

Name: Pimicotinib
Brand: Selleck Chemicals
SKU: E1727
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1727

Pimicotinib (ABSK021) is an orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R). It enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells having potential immunomodulatory and antineoplastic activities.

Chemical Structure

Molecular Weight: 420.47

Jump to

Quality Control

Batch: E172701 DMSO]84 mg/mL]false]Ethanol]21 mg/mL]false]Water]Insoluble]false Purity: 99.94%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.94

Related Targets	EGFR VEGFR FGFR PDGFR c-Met Src MEK FLT3 HER2 c-Kit
Other CSF-1R Inhibitors	Sotuletinib (BLZ945) GW2580 PLX5622 Ki20227 Edicotinib(JNJ-40346527) Sulfatinib CSF1R-IN-1 Vimseltinib AZD7507 Chiauranib

Solubility

In vitro
Batch:

DMSO : 84 mg/mL (199.77 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 21 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.200mg/ml (9.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 84 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.050mg/ml (2.50mM)	Taking the 1 mL working solution as an example, add 50 μL of 21 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	420.47	Formula	C₂₂H₂₄N₆O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	2253123-16-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	CSF1R
References	[1] https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.3100

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-10)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07499362	RECRUITING	Tenosynovial Giant Cell Tumor	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	2026-03-26	PHASE2
NCT07707882	NOT_YET_RECRUITING	Tenosynovial Giant Cell Tumor, Diffuse	Second Affiliated Hospital, Zhejiang University, School of Medicine	2027-10-01	PHASE2
NCT06186804	ENROLLING_BY_INVITATION	cGvHD	Abbisko Therapeutics Co, Ltd	2023-05-30	PHASE2
NCT06111274	RECRUITING	Advanced Pancreatic Cancer	Abbisko Therapeutics Co, Ltd	2023-10-17	PHASE2
NCT07210996	COMPLETED	Pharmacokinetics in Healthy Volunteers	Abbisko Therapeutics Co, Ltd	2025-09-12	PHASE1
NCT06884072	ACTIVE_NOT_RECRUITING	Healthy Subjects	Abbisko Therapeutics Co, Ltd	2025-04-08	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):